Minerva Rockets On Positive PhIIb Data – Is A Big Pharma Partnership On The Horizon?
Executive Summary
Minerva Neurosciences Inc.'s schizophrenia drug that targets patients with negative symptoms, an indication with high unmet need and no approved treatments, has met primary and secondary endpoints in a Phase IIb trial – positioning the company well for access to an open market and marking it as an attractive M&A target.
You may also be interested in...
Forum's Lead Drug Program Fails In Phase III Schizophrenia Trials
Forum Pharmaceuticals' lead compound encenicline has failed to meet the endpoints in two Phase III trials for the treatment of cognitive impairment in schizophrenia patients. .
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.